Effect of Astragalus and chemotherapy on the expression of VEGF in NSCLC, MVD and immune function
10.3969/j.issn.1005-1678.2017.07.036
- VernacularTitle:黄芪联合辅助化疗对NSCLC癌灶VEGF表达、MVD及免疫功能的影响
- Author:
Chang WANG
;
Shibo WU
- Keywords:
astragalus;
chemotherapy;
NSCLC;
VEGF;
microvessel density;
immune function
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(7):96-98
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Astragalus and chemotherapy on the expression of vascular endothelial growth factor(VEGF)in non-small cell lung cancer(NSCLC), microvessel density(MVD)and immune function.Methods 92 patients with NSCLC were divided into the study group and the control group, 46 cases in each group.Both groups were treated with neoadjuvant chemotherapy and operation, and the study group was treated with astragalus polysaccharide.The expression of VEGF in cancer tissues, MVD and immune function were compared between the two groups.The short-term and long-term curative effect and the incidence of adverse reactions were recorded.Results After treatment, positive rates of VEGF, MVD and blood CD8+ were significantly decreased in two groups (P<0.05), showing study groupcontrol group (P<0.05).There were no significant differences between the two groups in short-term curative effect and 5 year survival rates.The incidence rates of side effects in the study group were significantly lower than those in the control group (P<0.05).Conclusion Adjuvant chemotherapy combined with intravenous infusion of Astragalus Polysaccharide can improve MVD, the expression of VEGF and immune function in patients with NSCLC.
